-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, M15Djj7CunEJFs532a2Hzsva8DQptZ8M0JTu03cRJDZPvcABCd133VIrpzfz9hvI REd6uQU1Oss5/FpgvBbSeg== 0001181431-04-046093.txt : 20041004 0001181431-04-046093.hdr.sgml : 20041004 20041004134100 ACCESSION NUMBER: 0001181431-04-046093 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20040930 FILED AS OF DATE: 20041004 DATE AS OF CHANGE: 20041004 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CRITICAL PATH INC CENTRAL INDEX KEY: 0001060801 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 911788300 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 320 FIRST STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94105 BUSINESS PHONE: 4158088800 MAIL ADDRESS: STREET 1: 320 FIRST STREET CITY: SAN FRNACISCO STATE: CA ZIP: 94105 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CK Life Sciences Intl (Holdings) Inc CENTRAL INDEX KEY: 0001297567 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-25331 FILM NUMBER: 041061519 BUSINESS ADDRESS: STREET 1: 7TH FLOOR, CHEUNG KONG CENTER STREET 2: 2 QUEEN'S ROAD CENTRAL CITY: CENTRAL STATE: K3 ZIP: - BUSINESS PHONE: 852 2128 8888 MAIL ADDRESS: STREET 1: 7TH FLOOR, CHEUNG KONG CENTER STREET 2: 2 QUEEN'S ROAD CENTRAL CITY: CENTRAL STATE: K3 ZIP: - 4 1 rrd54184.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0202 4 2004-09-30 0 0001060801 CRITICAL PATH INC CPTH 0001297567 CK Life Sciences Intl (Holdings) Inc 7TH FLOOR, CHEUNG KONG CENTER 2 QUEEN'S ROAD CENTRAL HONG KONG K3 HONG KONG 0 0 1 0 Series E Preferred Stock 1.5 2004-09-30 4 J 0 6500000 D 2004-07-09 2008-07-09 Common Stock 6584093 6416667 I See footnote The shares of Series E Preferred Stock are convertible into the number shares of common stock of the issuer equal to the product of the number of shares of Series E Preferred Stock being converted multiplied by the quotient of (i) the Series E Accreted Value divided by (ii) $1.50 (subject to anti-dilution adjustments). Series E Accreted Value means, with respect to each share of Series E Preferred Stock, the sum of $1.50 plus all dividends that have accrued and compounded semi-annually. On September 30, 2004, through a privately negotiated transaction, Great Affluent Limited ("GAL") transferred 6,500,000 shares of the Issuer's Series E Preferred Stock to Ace Paragon Holdings Limited. GAL is a wholly owned subsidiary of CK Life Sciences Int'l., (Holdings) Inc. ("CKLS"). There is no expiration date by which the Series E Preferred Stock must convert into common stock. If at any date after July 9, 2007 the average closing price per share of common stock for any 60 consecutive trading days is not less than 400% of the Series E Accreted Value, then the issuer has the option to redeem within 30 days all outstanding Series E Preferred Stock for cash at a price per share equal to the Series E Accreted Value plus all dividends accrued since the previous semi-annual compounding date. On July 9, 2008, all Series E Preferred Stock must automatically be redeemed for cash at a price per share equal to the Series E Accreted Value plus all dividends accrued since the previous semi-annual compounding date. Not applicable. Immediately before the securities disposition by GAL in question, CKLS beneficially owned 12,916,667 shares of Series E Preferred Stock through GAL, convertible into 13,083,776 shares of Common Stock (including accretion of dividends as at September 30, 2004). After disposing of 6,500,000 shares of Series E Preferred Stock, GAL retains 6,416,667 shares of Series E Preferred Stock. /s/ IP Tak Chuen, Edmond, a director, on behalf of CKLS 2004-10-04 -----END PRIVACY-ENHANCED MESSAGE-----